Waldencast (WALD) Stock News

Waldencast (NASDAQ: WALD) reported Q2 2025 and H1 2025 results and provided a Q3 2025 trading update on Nov 24, 2025. Q2 2025 net revenue was $66.8M (+5.6% YoY) with Adjusted EBITDA margin of 5.0%. H1 2025 net revenue was $132.3M (+0.5% YoY) and net loss was $185.2M, driven by goodwill impairments of $132.1M (Obagi) and $20.0M (Milk Makeup). Q3 2025 net revenue was $67.8M (‑3.4% YoY); Obagi Medical grew to $42.6M (double‑digit) while Milk Makeup declined to $25.2M.

Strategic moves include FDA approval of Obagi Saypha MagIQ filler, acquisition of Novaestiq, sale of Obagi Japan trademark for $82.5M, credit facility refinancing, and a strategic review led by Lazard.

Obagi Medical (NASDAQ: WALD) presented new clinical data at the American Society for Dermatologic Surgery Annual Meeting, Nov 13–16, 2025 in Chicago.

Key highlights: Obagi saypha ChIQ pivotal randomized multicenter trial showed non-inferiority to Juvéderm Voluma XC for midface augmentation with high patient satisfaction and robust safety across diverse skin types; the abstract was selected as a top 10 oral presentation. Interim 3-month data for Nu-Cil BioStim Scalp Serum reported improvements in scalp health and hair appearance. saypha ChIQ is under FDA review; Obagi saypha MagIQ is FDA approved.

Waldencast (NASDAQ: WALD) announced a $82.5 million sale of its rights to the “Obagi” trademark in Japan to Rohto Pharmaceutical and a new $225 million secured, three-year first-lien term loan facility with funds managed by Lumina Capital, with proceeds expected by Nov 17, 2025.

The company said Rohto previously paid royalties equal to 3% of net revenue to Waldencast for Obagi Medical in fiscal 2024. Waldencast intends to use most of the Rohto proceeds to repay a significant portion of the Lumina loan, repay existing facilities, and fund working capital and general corporate purposes. Lazard acted as financial advisor.

Waldencast (NASDAQ: WALD) said it expects to report Second Quarter Fiscal 2025 results and Q3 2025 financial results on November 24, 2025. The company indicated it does not plan to host a conference call for these releases due to an ongoing strategic review. Investors should watch the November 24 date for published results and any follow-up communications the company may provide after its strategic review concludes.

Obagi Medical (WALD) launched Nu-Cil® BioStim™ Scalp Serum on October 8, 2025, a leave-in scalp serum priced at $125 and sold on Obagi.com.

The product uses a BioStim™ Complex with biotin, amino acids, peptides, 18 nutrients, B vitamins, and phytoactives. In a six-month, double-blind clinical study the serum showed: 74% reduction in dry fallen hair at 3 months, 2.8% increase in hair count per cm² at 3 months, 52% hair volume improvement in under 6 months, and up to 97% decrease in dry fallen hair in less than six months, with some benefits visible after two weeks.

Waldencast (NASDAQ: WALD) has received FDA approval for Obagi® saypha® MagIQ™, an injectable hyaluronic acid gel under the Obagi Medical brand. This marks the company's entry into the U.S. HA dermal filler market, with launch planned for 2026. The product utilizes proprietary MACRO Core Technology to create a stable 3D HA matrix for natural-looking results.

The approval follows a successful pivotal study of 270 patients over 48 weeks, meeting primary and secondary endpoints. This expansion is expected to double Obagi Medical's total addressable market to $4.2 billion by 2029. The product, developed by Croma-Pharma GmbH, will be followed by additional products in the saypha® line, including Obagi® saypha® ChIQ™ pending FDA approval.

Waldencast (NASDAQ: WALD), a global beauty platform, reported mixed H1 2025 results with notable developments. Obagi Medical achieved double-digit growth in core strategic channels and completed the Novaestiq acquisition, doubling its U.S. addressable market. Milk Makeup delivered high-20s growth in U.S. retail sales in Q2, driven by Ulta Beauty expansion and Amazon Premium Beauty launch.

The company revised its FY 2025 guidance to low to mid-single digit revenue growth with adjusted EBITDA margins in the low to mid-teens. Waldencast announced a strategic review to maximize shareholder value and postponed H1 2025 earnings release for additional analysis. Key challenges included international market softness, retailer destocking, and out-of-stock issues, though improving.

Waldencast (NASDAQ: WALD) has announced the acquisition of Novaestiq Corp. and U.S. rights to the Saypha® hyaluronic acid injectable gel line. The strategic move expands Obagi Medical's portfolio beyond skincare into the dermal filler market, effectively doubling its addressable market to $4.2 billion by 2029.

The transaction terms include cash payment, ongoing royalties, and potential issuance of Waldencast class A shares representing approximately 7% of fully diluted shares, contingent on FDA approval and revenue milestones of $100 million and $200 million. The Saypha® line, currently pending FDA approval, is globally recognized and manufactured in Austria with distribution in over 80 countries.

This acquisition positions Obagi Medical to become a leading dermatological mega brand by combining medical-grade skincare with aesthetic treatments, supported by extensive clinical studies particularly focused on diverse skin types.

Waldencast (NASDAQ: WALD) reported Q1 2025 financial results with net revenue of $65.4 million, representing a 4.1% decline from Q1 2024. The company achieved a 76.4% Adjusted Gross Margin and $4.4 million in Adjusted EBITDA. Obagi Medical saw 7.1% growth with $36.2 million in revenue, while Milk Makeup declined 15.1% to $29.3 million. The company secured a new $205 million credit facility including a $175 million term loan and $30 million revolving credit facility. Despite Q1 challenges, management maintains confidence in achieving mid-teens revenue growth and mid-to-high teens adjusted EBITDA margin for fiscal 2025, supported by successful product launches and retail expansion.